Cullinan Therapeutics, Inc. Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2021 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Cullinan Therapeutics, Inc. annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2021 to Q1 2023.
  • Cullinan Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2023 was $0.000.
  • Cullinan Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was $5.4M.
  • Cullinan Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2021 was $0.000.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $0 +$19.6M Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q1 2022 -$19.6M -$19.6M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $0 Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.